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It’s a favorite device of politicians who wish to smear a rival
candidate. The late, unlamented Democratic Senator Joseph
McCarthy employed it, successfully, against leftists whose
careers he wished to destroy. The Republicans tried, un-
successfully, to use it against Barack Obama. In its simplest
form, it involves branding someone a Communist, or a
terrorist, or a criminal, because they have family or friends,
or possibly just casual acquaintances, who are Communists,
or terrorists, or criminals. It’s called guilt by association.
It’s been in the news lately because it’s also a favorite tactic
of genome biologists, but in this case its purposes are not
sinister. Scientifically, it goes by the name of genome-wide
association studies, though guilt by association is just as apt.
It’s an attempt to find connections between simple changes
in the coding sequence of genes and the risk for developing
complex diseases. A product of the human genome sequence
(and, one could almost say, a means of ensuring job security
for the hordes of sequencers who were responsible for that
project), genome-wide association studies represent the first
comprehensive attempt by the genomics community to
demonstrate a big payoff, in terms of benefits to human
health, for the enormous amounts that were spent on that
original project.
If there were world enough and time, as Andrew Marvel (or
was it Francis Collins?) would say, we would perform such
studies simply by sequencing the complete genomes of large
cohorts of people with, say, type II diabetes, or lung cancer,
or schizophrenia, or Alzheimer’s disease, and then letting
the computational folks sift through the resulting reams of
data to sort out the varying combinations of simple spelling
mistakes in many different genes that give rise to autism, or
stroke, and so on - and it’s quite likely that, when sequencing
costs come down sufficiently, this is exactly what we will do.
In the meantime, though, the effort is more restricted.
The current approach relies on data from the International
Human Haplotype Mapping (HapMap) Project, which aims
to determine the prevalence of common polymorphisms in
the human genome, and on the fact that genetic variance at
one locus can predict with high probability genetic variance
at an adjacent locus, typically over distances of 30,000 base
pairs of DNA, making it possible to map the common
variability - and, as we shall see, the key word here is
‘common’ - associated with the risk of a given disease simply
by genotyping approximately 500,000 judiciously chosen
markers in the genome of several thousand case subjects and
comparing the frequency of those markers with genotypes of
control subjects. Consequently, it has become relatively
routine to identify common variants (for example, those that
are present in more than 5% of the population) that confer
not a certainty but rather a risk of disease, typically with
odds ratios of 1.2 to 5.0.
But now, in a series of articles in the 15 April 2009 online
issue of the New England Journal of Medicine, a debate is
taking place between proponents of this approach and those
who argue that it will never succeed in revealing the genetic
basis for complex, polygenic disorders. The reason for this
scrutiny is the failure of most of the ongoing studies to find
any convincing link with common diseases. It had been
expected that the risk of getting cancer, diabetes, and so on
would be largely controlled by a relatively small number of
common variants, each of which conferred a significant risk,
but only a small number of disease-associated variants have
been found thus far, and, with a few exceptions, the risk they
seem to confer is quite small. As Hardy and Singleton frame
the question in one of four papers on the subject,
“…discussion has centered on evaluating how far such studies
will take us in understanding the risks and causes of disease -
and thus the time and resources that should be invested in
genotyping more case subjects with any one disease to garner
what many see as diminishing genetic returns.”
Because they rely on the HapMap, current studies identify
loci, not specific genes. Moreover, we currently have haplo-
type maps only from single nucleotide polymorphisms(SNPs) present in at least 5% of chromosomes of each of just
three groups of defined ancestry: Yoruban, Northern and
Western European, and Asian (Chinese and Japanese), so by
definition the markers are for rather common variants
(present at > 5% frequency) in the human population.
Underlying the project at present, then, is the assumption
that common diseases are associated with common varia-
tions. A further assumption is that, even if individual alleles
have only a small effect on one’s risk for a disease, each
contribution is large enough that a manageably small
number will sum to a significant effect. But what if each
contribution is very small?
In a companion perspective, Goldstein argues that very
many very small contributions is exactly the case and
questions the wisdom of continuing this strategy. He points
out that there are examples of its successful application: “For
example, when exposed to the anti-HIV drug abacavir, a
hypersensitivity reaction develops in more than half the
carriers of the HLA-B*5701 allele, whereas such a reaction
occurs in less than 5% of patients without this allele.
Similarly, just three common variants are sufficient to
explain 14% of the population variation in HIV-1 viral load.”
But, he continues, “with traits such as height or type 2
diabetes, it seems that an inordinate number of common
SNPs would be needed to account for a sizable fraction of
heritability… The apparently modest effect of common
variation on most human diseases and related traits
probably reflects the efficiency of natural selection in pro-
hibiting increases in disease-associated variants in the
population.” In other words, common diseases might well be
caused by many different combinations of a large number -
probably hundreds - of very rare variants, which would even
eliminate the utility of the SNP hunt in identifying pathways
leading to disease. “In pointing at everything,” Goldstein
writes, “genetics would point at nothing.”
Similar concerns are expressed by Kraft and Hunter in a
companion piece (although they favor continuing the
common variant hunt). “First, the relative risks that are
found to be conferred by common risk genotypes account for
only a small proportion of the sibling recurrence risk (or the
risk that a sibling will also have the disease of interest).
Second, in multivariate analyses of large epidemiologic data
sets in which a family history of a disease is a risk factor, the
inclusion of data regarding which subjects carry the known
associated variants only minimally reduces the risk
associated with a family history of the disease. Third, in the
case of diseases that have been the focus of several genome-
wide association studies, some alleles have been detected
more than once, but each study has identified multiple
alleles that were not identified in other studies, suggesting
that many more alleles remain to be discovered. These
factors suggest that many, rather than few, variant risk
alleles are responsible for the majority of the inherited risk
of each common disease.”
One truly surprising result from the studies thus far is that
the majority of loci identified as associated with disease risk
do not map to the coding regions of individual genes.
Instead, they possibly affect either the splicing of the
messenger RNA or the sequences of microRNAs that
regulate gene expression. Deducing the effects of non-coding
changes on the level of active protein(s) in the cell is simply
not possible from first principles at the moment; it will
require huge experimental efforts in multiple laboratories.
So all this really seems very discouraging, but I have a
modest proposal for a somewhat altered approach that I
think could yield exciting results rapidly. The problem with
most fishing expeditions, which is what genome-wide
association studies are, is that one is never sure that one is
fishing where the fish are. My proposal is to focus on where
we know there are fish (or, to use another analogy, to look
for the keys under the lamppost because that’s where the
light is). That seems unlikely to provide new information,
but hear me out. I think the mistake we’re making is in
looking at the association between SNPs, many of which
mean little or nothing, and disease. What we should be doing
is looking at the association between diseases.
There are literally hundreds of inherited metabolic dis-
orders, most of which are autosomal recessive - they require
mutation in both copies of the gene in question to produce
the disease. In many cases there are dozens or even more
than a hundred known alleles in the gene in question, any
two of which suffice. Carriers for these diseases have just a
single variant and are usually free from symptoms of the
disease. But it is slowly becoming clear that for at least
some of the inborn errors of metabolism, the carriers are at
altered risk for something else. It may be that a carrier has a
reduced risk for an infectious disease, but often I think a
problem with a metabolic enzyme will produce haploinsuf-
ficiency in some pathway that is involved in a very different
disorder. Thus, carriers for the recessive, lysosomal storage
disorder Gaucher disease are almost an order of magnitude
more likely to develop Parkinson’s disease. Is the
connection through lysosomal dysfunction? Maybe, and
that’s testable: it suggests that carriers for other lysosomal
storage diseases such as Niemann-Pick, Tay-Sachs,
Anderson-Fabray, and Pompe’s diseases should also be at
increased risk for Parkinson’s and perhaps other neuro-
logical disorders.
That’s exactly the sort of thing a genome-wide association
study could determine, and it would shed valuable light on
the causes of a class of common diseases. I think it’s almost
guaranteed to turn up things, because metabolism is tied
into all the other pathways in the cell, and because by
definition the carrier alleles for a recessive disorder are
mutations that must have some definite effect on the
expression or function or stability of the protein in
question.
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genetic loci (the carrier frequency for Gaucher’s is estimated to
be 1 in 100 in the general population, and around in 1 in 20
among Ashkenazi Jews) that we know have physiological
consequences, and ask whether they are associated with the
risk for other, more common diseases. I think that’s where the
interesting connections are most likely to be found, at least
until we can sequence lots of whole genomes very cheaply.
After all, in a real criminal case, the police usually focus on
suspects they know are likely to be guilty, because they have
already been proven guilty of other things in the past. That’s
guilt by association, to be sure, but it tends to work.
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